posted on 2013-11-22, 00:00authored bySophie A. Fillon, J. Kirk Harris, Brandie D. Wagner, Caleb J. Kelly, Mark J. Stevens, Wendy Moore, Rui Fang, Shauna Schroeder, Joanne C. Masterson, Charles E. Robertson, Norman R. Pace, Steven J. Ackerman, Glenn T. Furuta
A growing number of studies implicate the microbiome in the pathogenesis of intestinal inflammation. Previous work has
shown that adults with esophagitis related to gastroesophageal reflux disease have altered esophageal microbiota
compared to those who do not have esophagitis. In these studies, sampling of the esophageal microbiome was
accomplished by isolating DNA from esophageal biopsies obtained at the time of upper endoscopy. The aim of the current
study was to identify the esophageal microbiome in pediatric individuals with normal esophageal mucosa using a minimally
invasive, capsule-based string technology, the EnterotestTM. We used the proximal segment of the Enterotest string to
sample the esophagus, and term this the ‘‘Esophageal String Test’’ (EST). We hypothesized that the less invasive EST would
capture mucosal adherent bacteria present in the esophagus in a similar fashion as mucosal biopsy. EST samples and
mucosal biopsies were collected from children with no esophageal inflammation (n = 15) and their microbiome composition
determined by 16S rRNA gene sequencing. Microbiota from esophageal biopsies and ESTs produced nearly identical profiles
of bacterial genera and were different from the bacterial contents of samples collected from the nasal and oral cavity. We
conclude that the minimally invasive EST can serve as a useful device for study of the esophageal microbiome.
Funding
The authors recognize the support of REDCap for subjects’ database supported by the National Center for Research Resources and the National Center
for Advancing Translational Sciences, National Institutes of Health, Colorado CTSI Grant Number UL1 RR025780. This work was supported by the American
Partnership For Eosinophilic Disorders (APFED) Junior Faculty HOPE Research Grant (SF); National Center for Research Resources and the National Center for
Advancing Translational Sciences, National Institutes of Health, Colorado CTSI Grant Number KL2 RR025779 (SF) and UL1 RR025780 (GTF) and the Campaign
Urging Research for Eosinophilic Diseases (CURED) (SJA/GTF).